Generate Biomedicines, Inc. (GENB) Insider Trading -- Recent Executive & Director Transactions

19 insiders reported 128 Form 4 transactions for Generate Biomedicines, Inc. (GENB) over the past 18 months (most recent 2026-03-06). Recent activity: Nally Michael (Chief Executive Officer) Buy 20,000 shares, Flagship VentureLabs VI LLC (Insider) Buy 13.7M shares, Bancel Stephane (Director) Buy 724,160 shares, FPN II, L.P. (Insider) Buy 12.7M shares, Flagship Pioneering Special Opportunities Fund II, L.P. (Insider) Buy 12.7M shares. Source: SEC Form 4.

DateInsiderTitleTypeSharesValue
2026-03-06Nally MichaelChief Executive OfficerBuy20,000$240,000
2026-03-02Flagship VentureLabs VI LLCInsiderBuy13.7M$0
2026-03-02Bancel StephaneDirectorBuy724,160$0
2026-03-02FPN II, L.P.InsiderBuy12.7M$0
2026-03-02Flagship Pioneering Special Opportunities Fund II, L.P.InsiderBuy12.7M$0
2026-03-02Flagship VentureLabs VI LLCInsiderBuy12.7M$0
2026-03-02Nutritional Health LTP Fund, L.P.InsiderBuy12.7M$0
2026-03-02Flagship Pioneering Fund VI, L.P.InsiderBuy12.7M$0
2026-03-02AFEYAN NOUBARDirectorBuy12.7M$0
2026-03-02Flagship Pioneering Fund VII, L.P.InsiderBuy12.7M$0
2026-03-02Flagship Pioneering Special Opportunities Fund II, L.P.InsiderBuy13.7M$0
2026-03-02Flagship Pioneering Fund VII, L.P.InsiderBuy13.7M$0
2026-03-02Nally MichaelChief Executive OfficerBuy658,327$0
2026-03-02Nutritional Health LTP Fund, L.P.InsiderBuy13.7M$0
2026-03-02FPN II, L.P.InsiderBuy13.7M$0
2026-03-02Flagship Pioneering Fund VI, L.P.InsiderBuy13.7M$0
2026-03-02AFEYAN NOUBARDirectorBuy13.7M$0
2026-03-02Flagship Pioneering Special Opportunities Fund II, L.P.InsiderBuy987,491$0
2026-03-02Flagship Pioneering Fund VI, L.P.InsiderBuy987,491$0
2026-03-02Flagship VentureLabs VI LLCInsiderBuy987,491$0
2026-03-02FPN II, L.P.InsiderBuy987,491$0
2026-03-02Nutritional Health LTP Fund, L.P.InsiderBuy987,491$0
2026-03-02AFEYAN NOUBARDirectorBuy987,491$0
2026-03-02Flagship Pioneering Fund VII, L.P.InsiderBuy987,491$0
2026-03-02Nutritional Health LTP Fund, L.P.InsiderBuy2.8M$0

Source: SEC Form 4 filings · as of 2026-03-06